Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Pipeline Report, H1 2017 - Review of 14 Companies and Drug Profiles - Research and Markets
Global Glomerulonephritis Therapeutics Pipeline Report H1 2017 - Review of 17 Companies & Drug Profiles - Research and Markets
UPDATE: Idaho Republican Labrador concedes it 'wasn't very elegant' to say no one dies because they lack health-care access
Idaho Republican Labrador concedes it 'wasn't very elegant' to say no one dies because of lack of health-care access
Myasthenia Gravis Forecast in 26 Major Markets 2017-2027 - Research and Markets
There is a small number of high-quality industrials-sector ETFs from which to choose.
A look back at the winners and losers of the final quarter of a tumultuous year.
The author does not own any of the stocks or funds mentioned above.
Most mutual fund managers do not focus on aftertax performance, but astute investors may be able to improve their aftertax returns.
©2010 Research Affiliates, LLC. The material contained in this document is for general information purposes only. It relates only to a hypothetical model of past performance of the Fundamental Index® strategy itself, and not to any asset management products based on this index. No allowance has been made for trading costs or management fees which would reduce investment performance. Actual results may differ. This material is not intended as an offer or a solicitation for the purchase and/or sale of any security or financial instrument, nor is it advice or a recommendation to enter into any transaction. This material is based on information that is considered to be reliable, but Research Affiliates® and its related entities (collectively “ RA ”) make this information available on an “as is” basis and make no warranties, express or implied regarding the accuracy of the information contained herein, for any particular purpose. RA is not responsible for any errors or omissions or for results obtained from the use of this information. Nothing contained in this material is intended to constitute legal, tax, securities, financial or investment advice, nor an opinion regarding the appropriateness of any investment. The general information contained in this material should not be acted upon without obtaining specific legal, tax or investment advice from a licensed professional. Indexes are not managed investment products, and, as such cannot be invested in directly. Returns represent back-tested performance based on rules used in the creation of the index, are not a guarantee of future performance and are not indicative of any specific investment. Research Affiliates, LLC, is an investment adviser registered under the Investment Advisors Act of 1940 with the U.S. Securities and Exchange Commission (SEC). Russell Investment Group is the source and owner of the Russell Index data contained or reflected in this material and all trademarks and copyrights related thereto. The presentation may contain confidential information and unauthorized use, disclosure, copying, dissemination, or redistribution is strictly prohibited. This is a presentation of RA . Russell Investment Group is not responsible for the formatting or configuration of this material or for any inaccuracy in RA ’s presentation thereof. The trade names Fundamental Index®, RAFI®, the RAFI logo, and the Research Affiliates corporate name and logo are registered trademarks and are the exclusive intellectual property of RA . Any use of these trade names and logos without the prior written permission of RA is expressly prohibited. RA reserves the right to take any and all necessary action to preserve all of its rights, title and interest in and to these terms and logos. Fundamental Index®, the non-capitalization method for creating and weighting of an index of securities, is patented and patent-pending proprietary intellectual property of Research Affiliates, LLC (US Patent No. 7,620,577; Patent Pending Publ. Nos. US-2005-0171884-A1, US-2006-0149645-A1, US-2007-0055598-A1, US-2008-0288416-A1, WO 2005/076812, WO 2007/078399 A2, WO 2008/118372, EPN 1733352, and HK1099110).